Daily Dilution Report - Apr 9, 2026
All Events
$BETR (MC: $519M)
- Public Offering: 1.88M Class A shares @ $32.00/share, raising up to $69M. Delivery ~Apr 9, 2026.
- Warrants: 9.81M Class A shares issuable upon exercise @ $575.00 avg. Exp. Aug 2028.
- Convertible Shares: 5.81M Class B & C shares convertible 1:1 to Class A.
$FERA (MC: $323M)
- No specific pre-business combination dilution instruments described in filing.
$TBN (MC: $809M)
- Public Offering: 2.95M shares at $35.00/share ($103.48M). Underwriters option for 0.44M additional shares.
- Registered Direct: Up to 2.26M shares to be offered at $35.00/share, raising up to $79.33M via entitlement offer.
- Acquisition & Plans: 6.53M shares to be issued for Falcon Acquisition consideration; 1.7M shares reserved for equity plans.
$CCCC (MC: $240M)
- The filing details a Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. While this agreement involves upfront payments, milestone payments, and royalties, it does not represent a direct issuance of equity that would dilute existing shareholders in the manner of the requested categories.
$WSR (MC: $871M)
- This filing does not contain any of the typical stock dilution instruments such as warrants, convertible notes, convertible preferred stock, ATM programs, equity lines, direct offerings, PIPE deals, or stock compensation plans with shares reserved.
- The document describes a merger agreement where Whitestone REIT (WSR) is being acquired. In this transaction, all outstanding common shares of beneficial interest will be canceled and converted into the right to receive cash. This is a takeout of existing shareholders, not a dilutive event.
$FBRX (MC: $365M)
- Public Offering: $150M gross proceeds for 5.71M shares at $26.27/share.
- Underwriters' Option: Additional 0.86M shares (~$22.5M) at $26.27/share exercisable for 30 days.
$FBRX (MC: $365M)
- Options for 2.62M shares outstanding at a weighted-average exercise price of $15.62 per share.
- Pre-funded Warrants for 4.88M shares outstanding (exercise price not provided).
- An additional 1.83M shares are reserved for future issuance or issuable upon vesting (RSUs, Equity Incentive, Inducement, and ESPP plans).
$NUAI (MC: $235M)
- Public offering of common stock (shares TBD) and an over-allotment option for additional shares.
- $50.0M SharonAI convertible note, ~11.5M potential shares at $0.87 floor; plus 17.7M shares from outstanding warrants.
- Up to $350.0M S-3 shelf registration for future equity/debt offerings.
$BIT (MC: $546M)
- ATM offering of up to 19M common shares.
- Potential proceeds ~$236.1M, at an assumed $12.56/share.
- Sales through "at the market" transactions on NYSE.
$AEHR (MC: $1.9B)
- ATM Program for up to $60M, sales in "at the market" offerings.
- Potential dilution from ~4.6M shares: 426K outstanding options ($4.97 avg) & 985K RSUs, plus ~3.22M shares reserved for future awards/ESPP.
$NUAI (MC: $235M)
- Warrants issued to Macquarie for up to 1.16M shares, with a minimum exercise price of $4.30/share.
- Direct offering of 1.0M shares @ $5.00/share to Macquarie.
- Required underwritten equity offering to raise >= $30M net proceeds within 60 days (details pending).
$XWIN (MC: $311M)
- The filing describes a material definitive agreement for an AI inference platform deployment and service. It involves a fixed fee of US$400,000, with an initial payment of US$200,000 and the remainder due upon acceptance. This is a service agreement and does not involve the issuance of new equity, warrants, convertible instruments, or other dilutive securities.
$AEHR (MC: $1.9B)
- ATM Program: Up to $60M common stock.
- Sales "at the market" via William Blair & Co. and Craig-Hallum.
- Company to pay agents up to 3.0% commission.